Jason Rizzo, MD, PhD: Evaluating Melanoma-specific Survival Stratification and Survival Benefit of Gene Testing in Patients with Melanoma

Dr. Rizzo presents research from the 2025 AAD Annual Meeting demonstrating the real-world impact of the 31-gene expression profile (31-GEP) test in patients with cutaneous melanoma. Using a large, unselected cohort of nearly 10,000 patients from SEER Program data, the study validated the test’s ability to stratify melanoma-specific survival and showed an associated survival benefit in patients who underwent 31-GEP testing.

Topics Covered

• Validation of the 31-GEP test in a large, real-world patient cohort
• Melanoma-specific survival stratification across risk groups
• Evidence of improved survival outcomes in tested patients
• The role of gene expression profiling in guiding clinical decision-making

Reference
Rizzo JM, Petkov VI, Kim YJ, et al. Real-world data demonstrate the 31-GEP stratifies risk of melanoma-specific mortality and is associated with improved survival: A SEER collaboration. Presented at the 2025 AAD Annual Meeting; March 6–11, 2025; Orlando, Florida.

Explore Related Resources

• Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test
• Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling
• Assessing the Prognostic Significance of the 31-gene Expression Profile Test